This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Rebecca G. Bakker-Arkema, MS; Michael H. Davidson, MD; Robert J. Goldstein, MD; Jean Davignon, MD; Jonathan L. Isaacsohn, MD; Stuart R. Weiss, MD; Leonard M. Keilson, MD; W. Virgil Brown, MD; Valery T. Miller, MD; Linda J. Shurzinske, MS; Donald M. Black, MD

JAMA. 1996;275(2):128-133.

Abstract
Objective.
—To assess the lipid-lowering effect of atorvastatin (a new 3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitor) on levels of serum triglycerides and other lipoprotein fractions in patients with primary hypertriglyceridemia, determine if atorvastatin causes a redistribution of triglycerides in various lipoprotein fractions, and assess its safety by reporting adverse events and clinical laboratory measurements.

Design.
—Randomized double-blind, placebo-controlled, parallel-group, multicenter trial.

Setting.
—Community- and university-based research centers.

Patients.
—A total of 56 patients (aged 26 to 74 years) with a mean baseline triglyceride level of 6.80 mmol/L (603.3 mg/dL) and a mean baseline low-density lipoprotein cholesterol (LDL-C) level of 3.07 mmol/L (118.7 mg/dL).

Interventions.
—Cholesterol-lowering diet (National Institutes of Health National Cholesterol Education Program Step I Diet) and either 5 mg, 20 mg, or 80 mg of atorvastatin, or placebo.

Main Outcome Measures.
—Percent change from baseline in total triglycerides for three dose levels of atorvastatin compared with placebo.

Results.
—Mean reductions in total triglycerides between 5 mg, 20 mg, and 80 mg of atorvastatin and placebo after 4 weeks of treatment were —26.5%, —32.4%, —45.8%, and —8.9%, respectively. Mean reductions in LDL-C were —16.7%, —33.2%, —41.4%, and —1.4%, respectively, and very low-density lipoprotein cholesterol (VLDL-C) were —34.3%, —45.9%, —57.7%, and —5.5%, respectively. Similar mean changes in total apolipoprotein B (apo B) (—16.9%, —32.8%, —41.7%, and + 1.0%), apo B in LDL (—14.8%, —29.8%, —42.0%,and —3.1%),and apo B in VLDL (—23.8%, —35.8%, —34.4%, and +11.7%) were observed. In addition, comparable mean changes in LDL triglycerides (—22.5%, —30.7%, —39.9%, and +3.9%) and VLDL triglycerides (—28.1%, —34.0%, —47.3%, and —10.8%) were seen.

Conclusions.
—In atorvastatin treatment groups, total serum triglyceride levels decreased in a dose-dependent manner; reductions in the 20-mg and 80-mg groups were statistically significant (P<.05) compared with placebo. Atorvastatin did not cause a redistribution of triglycerides but consistently lowered triglycerides in all lipoprotein fractions. Atorvastatin was well tolerated.

(JAMA. 1996;275:128-133)

Author Affiliations
From Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co, Ann Arbor, Mich (Mss Bakker-Arkema and Shurzinske and Dr Black); Chicago (Ill) Center for Clinical Research (Dr Davidson); Clinical Research Institute, Montreal, Quebec (Dr Davignon); Christ Hospital Cardiovascular Research Center, Cincinnati, Ohio (Dr Isaacsohn); San Diego (Calif) Endocrine and Medical Clinic Inc (Dr Weiss); Clinical Research Management, Center for Lipids, Portland, Me (Dr Keilson); Division of Arteriosclerosis and Lipid Metabolism, Emory University School of Medicine, Atlanta, Ga (Dr Brown); and Lipid Research Clinic, George Washington University Medical Center, Washington, DC (Dr Miller). Dr Goldstein is in private practice in Tampa, Fla.

Footnotes
Mss Bakker-Arkema and Shurzinske and Dr Black are employees of Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co, and own stock and hold options to purchase further stock in the company.

Reprint requests to Parke-Davis Pharmaceutical Research, 2800 Plymouth Rd, Ann Arbor, Ml 48105-1047 (Ms Bakker-Arkema).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Novel Management of Isotretinoin-Induced Hypertriglyceridemia in an Adolescent With Severe Acne
Beach et al.
CLIN PEDIATR 2009;48:551-554.
 

The Metabolic Syndrome
Cornier et al.
Endocr. Rev. 2008;29:777-822.
ABSTRACT | FULL TEXT  

Influence of Atorvastatin on Apolipoprotein E and AI Kinetics in Patients with Type 2 Diabetes
Bach-Ngohou et al.
J. Pharmacol. Exp. Ther. 2005;315:363-369.
ABSTRACT | FULL TEXT  

Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect
Zhou et al.
CMAJ 2005;172:1187-1194.
ABSTRACT | FULL TEXT  

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
Bilz et al.
J. Lipid Res. 2004;45:174-185.
ABSTRACT | FULL TEXT  

Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients
Lins et al.
Nephrol Dial Transplant 2003;18:967-976.
ABSTRACT | FULL TEXT  

Apolipoprotein[a] secretion from hepatoma cells is regulated in a size-dependent manner by alterations in disulfide bond formation
Nassir et al.
J. Lipid Res. 2003;44:816-827.
ABSTRACT | FULL TEXT  

Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LIPC promoter variant
Berk-Planken et al.
Diabetes Care 2003;26:427-432.
ABSTRACT | FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Atorvastatin Reduces Postprandial Accumulation and Cholesteryl Ester Transfer Protein-Mediated Remodeling of Triglyceride-Rich Lipoprotein Subspecies in Type IIB Hyperlipidemia
Guerin et al.
J. Clin. Endocrinol. Metab. 2002;87:4991-5000.
ABSTRACT | FULL TEXT  

Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia
van Dam et al.
Heart 2002;88:234-238.
ABSTRACT | FULL TEXT  

Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia
Athyros et al.
Diabetes Care 2002;25:1198-1202.
ABSTRACT | FULL TEXT  

Aggressive Lipid Lowering Does Not Improve Endothelial Function in Type 2 Diabetes: The Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial
van Venrooij et al.
Diabetes Care 2002;25:1211-1216.
ABSTRACT | FULL TEXT  

The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia: The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
The Diabetes Atorvastatin Lipid Intervention DALI
Diabetes Care 2001;24:1335-1341.
ABSTRACT | FULL TEXT  

Repeated Analysis of Semen Parameters in Beagle Dogs during a 2-Year Study with the HMG-CoA Reductase Inhibitor, Atorvastatin
Dostal et al.
Toxicol Sci 2001;61:128-134.
ABSTRACT | FULL TEXT  

Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis
Hufnagel et al.
Nephrol Dial Transplant 2000;15:684-688.
ABSTRACT | FULL TEXT  

Not Acute but Chronic Hypertriglyceridemia Is Associated With Impaired Endothelium-Dependent Vasodilation : Reversal After Lipid-Lowering Therapy by Atorvastatin
de Man et al.
Arterioscler. Thromb. Vasc. Bio. 2000;20:744-750.
ABSTRACT | FULL TEXT  

Action of Atorvastatin in Combined Hyperlipidemia : Preferential Reduction of Cholesteryl Ester Transfer From HDL to VLDL1 Particles
Guerin et al.
Arterioscler. Thromb. Vasc. Bio. 2000;20:189-197.
ABSTRACT | FULL TEXT  

Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points
Bucher et al.
JAMA 1999;282:771-778.
FULL TEXT  

Drug Treatment of Lipid Disorders
Knopp
NEJM 1999;341:498-511.
FULL TEXT  

Metabolism and Excretion of Atorvastatin in Rats And Dogs
Black et al.
Drug Metab. Dispos. 1999;27:916-923.
ABSTRACT | FULL TEXT  

Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias
Wierzbicki et al.
QJM 1999;92:387-394.
ABSTRACT | FULL TEXT  

Select 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Vary in Their Ability to Reduce Egg Yolk Cholesterol Levels in Laying Hens through Alteration of Hepatic Cholesterol Biosynthesis and Plasma VLDL Composition
Elkin et al.
J. Nutr. 1999;129:1010-1019.
ABSTRACT | FULL TEXT  

Natural Statins and Stroke Risk
Furberg
Circulation 1999;99:185-188.
FULL TEXT  

The HMG-CoA Reductase Inhibitor Atorvastatin Increases the Fractional Clearance Rate of Postprandial Triglyceride-Rich Lipoproteins in Miniature Pigs
Burnett et al.
Arterioscler. Thromb. Vasc. Bio. 1998;18:1906-1914.
ABSTRACT | FULL TEXT  

Maximizing the Cost-effectiveness of Lipid-Lowering Therapy
Jacobson et al.
Arch Intern Med 1998;158:1977-1989.
ABSTRACT | FULL TEXT  

Toxic Epidermal Necrolysis From Atorvastatin
Pfeiffer et al.
JAMA 1998;279:1613-1614.
FULL TEXT  

An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
Black et al.
Arch Intern Med 1998;158:577-584.
ABSTRACT | FULL TEXT  

The Effect of Atorvastatin on the Human Lens After 52 Weeks of Treatment
Reid et al.
J CARDIOVASC PHARMACOL THER 1998;3:71-76.
ABSTRACT  

Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia
Dallongeville et al.
J CARDIOVASC PHARMACOL THER 1998;3:103-110.
ABSTRACT  

A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin
Schrott et al.
J CARDIOVASC PHARMACOL THER 1998;3:119-123.
ABSTRACT  

Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs
Burnett et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:2589-2600.
ABSTRACT | FULL TEXT  

Efficacy and Safety of a New Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, Atorvastatin, in Patients with Combined Hyperlipidemia: Comparison with Fenofibrate
Ooi et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:1793-1799.
ABSTRACT | FULL TEXT  

Cholesterol and Coronary Heart Disease: The 21st Century
Grundy
Arch Intern Med 1997;157:1177-1184.
ABSTRACT  

Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients with Hypercholesterolemia
Isaacsohn et al.
J CARDIOVASC PHARMACOL THER 1997;2:243-249.
ABSTRACT  

A New Statin Lowers Triglycerides
Journal Watch Cardiology 1996;1996:20-20.
FULL TEXT  

A NEW STATIN LOWERS TRIGLYCERIDES
JWatch General 1996;1996:5-5.
FULL TEXT